daiichisankyo.us Open in urlscan Pro
52.168.54.37  Public Scan

Form analysis
1 forms found in the DOM

Name: hrefFm — POST #

<form action="#" id="hrefFm" method="post" name="hrefFm"><span></span></form>

Text Content

Skip to content
Passion for innovation. Compassion for Patients.
Healthcare Professionals | Careers | Contact Us | Worldwide |
Search Search Search

 * About Us
   * About Us
   
   
   * WHO WE ARE
     
     * Values and Mission
     * Company Culture
     * Global Business Strategy and Midterm Plan
     * History
     * Corporate Philanthropy
   
   
   * PARTNERSHIPS
     
     * Business Development
     * Alliances At-A-Glance
   
   
   * CORPORATE INFORMATION
     
     * Corporate Management
     * Company Governance and Global Structure
   
   
   * PATIENT ADVOCACY
 * Responsibility
   * Responsibility
   
   
   * COMPLIANCE
     
     * Standards Of Business Conduct
     * Standards of Business Conduct & Ethics for Third Parties
     * Daiichi Sankyo Group Global Anti-Bribery and Anti-Corruption Policy
     * California Compliance Declaration
     * California Supply Chains Act
     * Daiichi Sankyo Group Global Business Partner Code of Conduct
   
   
   * TRANSPARENCY AND DISCLOSURE
     
     * Post-marketing Commitments
     * CME and Charitable Contributions Disclosure
     * Working with Healthcare Professionals
     * Vermont Pharmaceutical Marketer Price Disclosure
     * Clinical Trial Information Disclosure
   
   
   * CORPORATE GIVING AND SUPPORT
     
     * Daiichi Sankyo Requirements
     * Charitable Contributions
     * Sponsorships
     * Corporate Support FAQs
     * Patient Advocacy Support
     * Independent Medical Education (IME)
   
   
   * DAIICHI SANKYO PATIENT SUPPORT PROGRAMS
   
   
   * SUPPLIER DIVERSITY
     
     * Supplier Registration
     * Supplier Diversity FAQs
   
   
   * TRANSPARENCY IN COVERAGE
   
   
   * RIGHTS & PROTECTIONS AGAINST SURPRISE MEDICAL BILLS
 * Research & Development
   * Research & Development
   * Our Pipeline
   * Worldwide R&D Operations
   * Clinical Trial Information Disclosure
   
   
   * EXPANDED ACCESS TO INVESTIGATIONAL PRODUCTS
   
   * External Sponsored Research (ESR) Investigator Initiated Studies (IIS) and
     Collaborative Research (CR)
 * Medicines
 * Media
 * Our Stories


Search Search Button
 * 
   About Us
   * 
     Who We Are
     * Who We Are
     * Values and Mission
     * Company Culture
     * Global Business Strategy and Midterm Plan
     * History
     * Corporate Philanthropy
   * 
     Partnerships
     * Partnerships
     * Business Development
     * Alliances At-A-Glance
   * 
     Corporate Information
     * Corporate Information
     * Corporate Management
     * Company Governance and Global Structure
   * Patient Advocacy
 * 
   Responsibility
   * 
     Compliance
     * Compliance
     * Standards Of Business Conduct
     * Standards of Business Conduct & Ethics for Third Parties
     * Daiichi Sankyo Group Global Anti-Bribery and Anti-Corruption Policy
     * California Compliance Declaration
     * California Supply Chains Act
     * Daiichi Sankyo Group Global Business Partner Code of Conduct
   * 
     Transparency and Disclosure
     * Transparency and Disclosure
     * Post-marketing Commitments
     * CME and Charitable Contributions Disclosure
     * Working with Healthcare Professionals
     * Vermont Pharmaceutical Marketer Price Disclosure
     * Clinical Trial Information Disclosure
   * 
     Corporate Giving and Support
     * Corporate Giving and Support
     * Daiichi Sankyo Requirements
     * Charitable Contributions
     * Sponsorships
     * Corporate Support FAQs
     * Patient Advocacy Support
     * Independent Medical Education (IME)
   * Daiichi Sankyo Patient Support Programs
   * 
     Supplier Diversity
     * Supplier Diversity
     * Supplier Registration
     * Supplier Diversity FAQs
   * Transparency in Coverage
   * Rights & Protections Against Surprise Medical Bills
 * 
   Research & Development
   * Our Pipeline
   * Worldwide R&D Operations
   * Clinical Trial Information Disclosure
   * Expanded Access to Investigational Products
   * External Sponsored Research (ESR) Investigator Initiated Studies (IIS) and
     Collaborative Research (CR)
 * Medicines
 * Media
 * Our Stories
 * Healthcare Professionals
 * Careers
 * Contact Us


BREADCRUMB

 * Home>
 * Medicines


PRODUCT_WITH_CATEGORY


MEDICINES

Daiichi Sankyo is dedicated to creating new standards of care by leveraging our
world-class science and technology. We currently have three innovative oncology
medicines approved in the U.S. to treat certain patients with breast, lung and
gastric cancer as well as acute myeloid leukemia and tenosynovial giant cell
tumor. Our other U.S. medicines include those to treat thrombosis, stroke risk
reduction and iron deficiency anemia.

Click to view Daiichi Sankyo medicines available in other countries:

Worldwide


U.S. MEDICINES


ENHERTU®

(fam-trastuzumab deruxtecan-nxki)

See full prescribing Information, including boxed warnings and medication guide.

Get more info
 * Patient site
 * HCP site
 * Patient access site
 * Prescribing Information
 * Medication Guide

Material Safety Data Sheet

--------------------------------------------------------------------------------


INJECTAFER®

(ferric carboxymaltose injection)

See full prescribing Information

Get more info
 * Corporate site
 * Patient site
 * HCP site
 * Prescribing Information

--------------------------------------------------------------------------------


SAVAYSA®

(edoxaban) tablets

See full prescribing Information, including boxed warnings and medication guide.

Get more info
 * Patient site
 * HCP site
 * Global consumer site
 * Prescribing Information
 * Medication Guide

Material Safety Data Sheet

--------------------------------------------------------------------------------


TURALIO®

(pexidartinib)

See full prescribing Information, including boxed warning regarding liver
toxicity and medication guide.

Get more info
 * Patient site
 * HCP site
 * REMS/Patient registry
 * HCP & patient access site
 * Prescribing Information
 * Medication Guide

Material Safety Data Sheet

--------------------------------------------------------------------------------


VANFLYTA®

(quizartinib)

See full prescribing Information, including boxed warning and medication guide.

Get more info
 * HCP Site
 * REMS
 * HCP & patient access site
 * Prescribing Information
 * Medication Guide

Material Safety Data Sheet

--------------------------------------------------------------------------------


HAVE A QUESTION ABOUT A MEDICINE?

Please call the Daiichi Sankyo Contact Center at 1-877-4DS-PROD
(1-877-437-7763) if you have a question about any of our medicines or to report
any adverse reactions to our medicines. To report negative side effects of
prescription drugs to the FDA, visit www.fda.gov/medwatch





 * ABOUT US
   
   * Who We Are
   * Partnerships
   * Corporate Information
   * Patient Advocacy


 * RESPONSIBILITY
   
   * Compliance
   * Transparency and Disclosure
   * Corporate Giving and Support
   * Daiichi Sankyo Patient Support Programs
   * Supplier Diversity
   * Transparency in Coverage
   * Rights & Protections Against Surprise Medical Bills


 * RESEARCH & DEVELOPMENT
   
   * Our Pipeline
   * Worldwide R&D Operations
   * Clinical Trial Information Disclosure
   * Expanded Access to Investigational Products
   * External Sponsored Research (ESR) Investigator Initiated Studies (IIS) and
     Collaborative Research (CR)
 * Medicines
 * Media


 * OUR STORIES

 * LinkedIn
 * Twitter
 * Facebook
 * Youtube

   
 * Terms & Conditions
 * Privacy Notice
 * Contact Us
 * Site Map

© 2023 Daiichi Sankyo, Inc. All Rights Reserved.
go to top


WORLDWIDE

Daiichi Sankyo Co., Ltd - Global


ASIA

 * Japan
 * China
 * Hong Kong
 * Korea
 * Taiwan
 * Thailand
 * Vietnam


AMERICAS

 * Brazil

USA

 * Daiichi Sankyo, Inc.
 * American Regent, Inc.
 * Plexxikon


EUROPE

 * Daiichi Sankyo
   Europe
 * Austria
 * Belgium
 * France
 * Germany
 * Ireland

 * Italy
 * Portugal
 * Spain
 * Switzerland
 * The Netherlands
 * Turkey
 * United Kingdom



Continue Return